Carcinoma of urethra
diseaseOn this page
Also known as carcinoma of the urethraurethra carcinomaurethral cancerurethral carcinoma
Summary
Carcinoma of urethra (MONDO:0021327) is a cancer (an umbrella term covering 5 Mondo subtypes) and 71 clinical trials. Top therapeutic interventions include cisplatin, cabozantinib, and vinblastine. A subtype of urethra cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 71
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | carcinoma of urethra |
| Mondo ID | MONDO:0021327 |
| NCIT | C9106 |
| SNOMED CT | 448954003 |
| UMLS | C3164789 |
| MedGen | 757195 |
| GARD | 0027891 |
| Anatomy (UBERON) | UBERON:0000057 |
| Is cancer (heuristic) | yes |
Also known as: carcinoma of the urethra · carcinoma of urethra · urethra carcinoma · urethral cancer · urethral carcinoma
Disease family
This is a subtype of urethra cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant urinary system neoplasm › urethra cancer › carcinoma of urethra
Related subtypes (4): male urethral cancer, female urethral cancer, posterior urethra cancer, anterior urethra cancer
Subtypes (5): urethra squamous cell carcinoma, urethra transitional cell carcinoma, urethra adenocarcinoma, Littre gland carcinoma, carcinoma in situ of urethra
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 71.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 44 |
| PHASE1 | 9 |
| Not specified | 8 |
| PHASE3 | 6 |
| PHASE1/PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05092958 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study |
| NCT00003376 | PHASE3 | COMPLETED | Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium |
| NCT00003701 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Patients With Bladder Cancer |
| NCT00014274 | PHASE2/PHASE3 | COMPLETED | Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium |
| NCT00022191 | PHASE3 | COMPLETED | Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer |
| NCT00942331 | PHASE3 | COMPLETED | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer |
| NCT03296306 | PHASE3 | UNKNOWN | Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma |
| NCT00082706 | PHASE2 | ACTIVE_NOT_RECRUITING | Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant |
| NCT03237780 | PHASE2 | ACTIVE_NOT_RECRUITING | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer |
| NCT03866382 | PHASE2 | RECRUITING | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
| NCT04848519 | PHASE2 | ACTIVE_NOT_RECRUITING | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma |
| NCT04940299 | PHASE2 | ACTIVE_NOT_RECRUITING | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma |
| NCT04953104 | PHASE2 | ACTIVE_NOT_RECRUITING | ARID1A and/or KDM6A Mutation and CXCL13 Expression |
| NCT05888532 | PHASE1/PHASE2 | RECRUITING | 64Cu-GRIP B in Patients With Advanced Malignancies |
| NCT05969860 | PHASE2 | RECRUITING | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer |
| NCT00002684 | PHASE2 | COMPLETED | Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer |
| NCT00002914 | PHASE2 | COMPLETED | Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract |
| NCT00003175 | PHASE2 | COMPLETED | Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer |
| NCT00004223 | PHASE2 | COMPLETED | Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer |
| NCT00004856 | PHASE2 | TERMINATED | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium |
| NCT00005644 | PHASE2 | COMPLETED | Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function |
| NCT00006026 | PHASE2 | COMPLETED | Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract |
| NCT00006111 | PHASE2 | COMPLETED | Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract |
| NCT00006351 | PHASE2 | COMPLETED | SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract |
| NCT00009867 | PHASE2 | COMPLETED | Arsenic Trioxide in Treating Patients With Urothelial Cancer |
| NCT00014144 | PHASE2 | COMPLETED | S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract |
| NCT00021099 | PHASE2 | COMPLETED | Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer |
| NCT00022633 | PHASE2 | TERMINATED | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract |
| NCT00045630 | PHASE2 | COMPLETED | S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium |
| NCT00053209 | PHASE2 | COMPLETED | Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium |
| NCT00055835 | PHASE2 | COMPLETED | S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium |
| NCT00066612 | PHASE2 | COMPLETED | S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy |
| NCT00072150 | PHASE2 | COMPLETED | Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma |
| NCT00080795 | PHASE2 | COMPLETED | Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium |
| NCT00087295 | PHASE2 | TERMINATED | S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium |
| NCT00112905 | PHASE2 | TERMINATED | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium |
| NCT00397488 | PHASE2 | COMPLETED | Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium |
| NCT00407485 | PHASE2 | COMPLETED | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium |
| NCT00471536 | PHASE2 | COMPLETED | Pazopanib in Treating Patients With Metastatic Urothelial Cancer |
| NCT00478361 | PHASE2 | COMPLETED | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 14 |
| CABOZANTINIB | 4 | 7 |
| VINBLASTINE | 4 | 4 |
| CARBOPLATIN | 4 | 3 |
| GEMCITABINE | 4 | 3 |
| PACLITAXEL | 4 | 3 |
| SUNITINIB MALATE | 4 | 3 |
| DOXORUBICIN HYDROCHLORIDE | 4 | 2 |
| PAZOPANIB HYDROCHLORIDE | 4 | 2 |
| ARSENIC TRIOXIDE | 4 | 1 |
| AVELUMAB | 4 | 1 |
| FLUDEOXYGLUCOSE F 18 | 4 | 1 |
| GEFITINIB | 4 | 1 |
| IXABEPILONE | 4 | 1 |
| LONAFARNIB | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| SORAFENIB | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| VANDETANIB | 4 | 1 |
| RUBITECAN | 3 | 1 |
| PIRITREXIM | 2 | 1 |
| CHEMBL48 | 0 | 3 |
| CHEMBL3109278 | 0 | 3 |
| CHEMBL4788494 | 0 | 2 |
| CHEMBL376464 | 0 | 2 |